Recorded June 30, 2021. Noble Capital Markets Senior Research Analyst Robert LeBoyer sits down Lineage Cell Therapeutics CEO Brian Culley for this exclusive interview. Topics covered include: Allogeneic approach to cell therapy – an off-the-shelf solutionScalability and control advantages to Lineage’s manufacturing processOpRegen – restoring retinal tissue with a single injection of RPE cells – advantage over current treatment methodsOPC1 – Spinal cord treatment program – using cell therapy to treat neurological conditionsVAC2 – A cancer vaccine candidate produced from their pluripotent cell tech, comprised of mature dendritic cells.Upcoming milestones & financial position for 2021 Read More >>